News for $NVLX - (Nuvilex, Inc. Phase III Clinic

  News for $NVLX - (Nuvilex, Inc. Phase III Clinical Trials in Strong Hands With Dr. Gerald  Crabtree) 
 
	 
 
 
 
NEW YORK, NY, Apr 01, 2013 (MARKETWIRE via COMTEX) -- Nuvilex, Inc. (OTCQB: 
 
NVLX) CEO, Dr. Robert Ryan knew exactly what he was doing two years ago when he 
 
announced Dr. Gerald Crabtree would be joining his team as the company's Chief 
 
Operating Officer (COO). Stock House Group, a full service investment relations 
 
firm focused on research, awareness and content development spoke with Dr. 
 
Crabtree and agrees he is the right guy, at the right place, at the right time, 
 
and his extensive expertise should help carry this small biotech across the 
 
finish line. 
 
 
 
Dr. Gerald Crabtree has spent more than forty of his 72 years studying cancer in 
 
one way or another -- from his time at Brown University from 1970-1985, a period 
 
that included work in the early 1980s at the Roger Williams Cancer Center on the 
 
clinical development of a cancer drug that was further developed by Eli Lilly, 
 
to his time in the 1990s with Bristol-Myers Squibb as part of the team that 
 
developed Taxol, a more than $11-billion drug for the company. 
 
 
 
Dr. Crabtree has worked with a number of companies, each time finding himself in 
 
a crucial role in the company's cancer research, development, and in many cases, 
 
its clinical trials, and says each experience has helped shape his understanding 
 
of the complex disease. "I have been blessed to have known and worked with some 
 
of the major players in the cancer field and to have been involved in the 
 
development of a major cancer drug like Taxol. But now, I am involved with 
 
something that may dwarf all of those achievements." 
 
 
 
And, that something is Nuvilex's unique and proprietary cell encapsulation or 
 
"Cell-in-a-Box" technology. The company has gone all in on "Cell-in-a-Box" with 
 
almost $30-million invested in the technology and landing Dr. Crabtree to help 
 
drive the success on its first big chance to show off in a large-scale Phase III 
 
clinical trial. 
 
 
 
Continue reading the rest of this article at  www.stockhousegroup.com/features   
 
 
 
About Stock House Group 
 
 
 
Stock House Group is a full service Investment Relations firm specializing in 
 
Awareness, Research, and Content Development. The firm offers a platform to CEOs 
 
to develop their story through the press, Research Reports, and CEO Interviews. 
 
At the same time, we're building a library of Research to assist Investors in 
 
their due diligence on small and large cap stocks.